Expertise in
3
conditions

Mai-szu W. Wu

No. 291, Zhongzheng Rd, 
Chung-ho, TPQ, TW 
Expertise in
3
conditions
No. 291, Zhongzheng Rd, 
Chung-ho, TPQ, TW 

Overview

Mai-szu Wu practices practicing medicine in Chung-ho, Taiwan.

Wu is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Chronic Kidney Disease, Pinworms, End-Stage Renal Disease (ESRD), IgA Nephropathy, and Kidney Transplant.

They are actively involved in clinical research, co-authoring 140 peer reviewed articles and participating in 6 clinical trials.

Locations

No. 291, Zhongzheng Rd, Chung-ho, TPQ 23561, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2026
Intervention Type: Drug
Study Drug: Atrasentan
Study Phase: Phase 3
A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy
A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy
Enrollment Status: Completed
Publish Date: June 01, 2026
Intervention Type: Drug
Study Drug: Mezagitamab
Study Phase: Phase 1
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS
Enrollment Status: Completed
Publish Date: April 17, 2026
Intervention Type: Drug
Study Drugs: Sparsentan, Irbesartan
Study Phase: Phase 3
A Phase 3 Study of PBF-1681 Comprising a 16-week, Placebo-controlled, Double-blind Randomized Period and an 8-week, Open-label Extension Period for the Treatment of Iron Deficiency Anemia in Patients With Non-Dialysis Dependent CKD
A Phase 3 Study of PBF-1681 Comprising a 16-week, Placebo-controlled, Double-blind Randomized Period and an 8-week, Open-label Extension Period for the Treatment of Iron Deficiency Anemia in Patients With Non-Dialysis Dependent CKD
Enrollment Status: Completed
Publish Date: June 29, 2025
Intervention Type: Drug
Study Drug: Ferric Citrate
Study Phase: Phase 3
A Phase I/II Study to Evaluate the Safety and Efficacy of Allogeneic Infusion of Adipose-Derived Stem Cells in Moderate to Severe Chronic Kidney Disease
A Phase I/II Study to Evaluate the Safety and Efficacy of Allogeneic Infusion of Adipose-Derived Stem Cells in Moderate to Severe Chronic Kidney Disease
Enrollment Status: Completed
Publish Date: February 09, 2024
Intervention Type: Drug
Study Drug: ELIXCYTE
Study Phase: Phase 1/Phase 2
A Long-Term, Open-Label, Prospective Phase IV Study to Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis
A Long-Term, Open-Label, Prospective Phase IV Study to Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis
Enrollment Status: Completed
Publish Date: January 13, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 5 Less Clinical Trials

140 Total Publications

Response to the comment on "Insights of fabry disease: Expert consensus approach for screening, diagnosis, and multidisciplinary management in chronic kidney disease".
Response to the comment on "Insights of fabry disease: Expert consensus approach for screening, diagnosis, and multidisciplinary management in chronic kidney disease".
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: April 08, 2026

Frequently Asked Questions about Mai-szu W. Wu

Is Mai-szu W. Wu a top-rated expert for Chronic Kidney Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Mai-szu W. Wu is classified as an Distinguished expert for Chronic Kidney Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Mai-szu W. Wu participate in research or clinical trials?

Yes. Mai-szu W. Wu has published 140 articles and abstracts on conditions like Chronic Kidney Disease. You can view a list of Mai-szu W. Wu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Wu's expertise for a condition
ConditionClose
    View All 22 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile